UCB Biopharma

UCB Biopharma We’re , a global biopharmaceutical company. We believe everyone deserves to live their best life.
💙 Inspired by patients 🔬 Driven by science

18/06/2026

When Candace was just 19, her symptoms began in a way she didn’t expect: first drooping eyelids, then double vision, followed by a rapid progression of challenges such as chewing, swallowing, speaking and pronouncing words.

Since then, myasthenia gravis ( ) has touched every aspect of her life. Even everyday moments can become unexpectedly hard, like difficulties walking or not being able to grip a knife when preparing food.

Together, we can raise awareness of MG. Learn more about Candace’s journey living with MG: https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG

17/06/2026

CDKL5 deficiency disorder (CDD) is an ultra-rare developmental and epileptic encephalopathy (DEE), with impacts that extend far beyond seizures alone.

For individuals and families, they can face complex care needs and constant coordination - with caregivers at the heart of everyday support.

That could mean coordinating appointments one day and advocating for support the next, all while navigating the daily demands of the condition.

International CDKL5 Awareness Day is another moment to look beyond the clinical descriptions of the condition and remember what daily life looks like for people living with this severe disease.

16/06/2026

At just 21, Alisa began experiencing symptoms she couldn’t explain – a weakened voice, slurred speech, and difficulty smiling and swallowing. What followed was a long and difficult journey to diagnosis, with her symptoms repeatedly dismissed for over a year.

Now, Alisa shares her story to help others understand the invisible impact of myasthenia gravis (MG). Through resilience and support, she continues to rebuild her confidence and raise awareness of MG, so others don’t feel alone.

This , let’s make the invisible visible.

Find out more about her story and the impact MG had on her life https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG

09/06/2026

For many people living with HS, getting a diagnosis can take years.

On average, people wait 7.3 years, delaying access to appropriate care, support, and understanding.

Through our commitment to improving care and recognition, we’re helping raise awareness of the realities of living with HS and the importance of earlier diagnosis.

Learn more in our HS Vision Progress and Commitment Report: https://bit.ly/4o1C5zY

04/06/2026

For many families, life with or is about so much more than seizures. It’s the developmental challenges, cognitive and behavioral difficulties, disrupted sleep, and the constant changing care that shape each day.

With June marking Dravet Syndrome Awareness Month and CDKL5 Deficiency Disorder (CDD) Awareness Month, it’s an important time to listen to people living with developmental and epileptic encephalopathies (DEEs) and understand the challenges the diseases present across the care journey

As conversations continue across the rheumatology community at  , it’s important to challenge some common myths about wh...
04/06/2026

As conversations continue across the rheumatology community at , it’s important to challenge some common myths about what axSpA really looks like.

Looking beyond back pain helps build a fuller understanding of inflammatory disease and supports more informed conversations, awareness and recognition.

👉 Swipe to explore an axSpA myth.

For many people with psoriasis, joint pain, stiffness or swelling are early signs of psoriatic arthritis (PsA) that are ...
03/06/2026

For many people with psoriasis, joint pain, stiffness or swelling are early signs of psoriatic arthritis (PsA) that are often missed.

When the connection between skin and joint symptoms is overlooked, conversations and support can be delayed.

Building understanding of the shared inflammation beneath the surface is key to better long-term outcomes.

As the global rheumatology community comes together at and beyond, awareness and shared learning remain vital.

02/06/2026

HS can affect daily life in ways that aren’t always visible.

Through our commitment to improving care and understanding, we’re helping bring more attention to the lived experiences of people affected by HS, and why earlier recognition and support matter so much.

📖 Learn more in our HS Vision Progress and Commitment Report: https://bit.ly/4o1C5zY

27/05/2026

Developmental and epileptic encephalopathies (DEEs), which are rare, severe, and lifelong neurological disorders, are about .

DEEs can cause an increased risk of mortality, including sudden unexpected death in epilepsy (SUDEP), as well as behavioral, cognitive and sleep-related challenges.

Adres

Allée De La Recherche 60
Brussels
1070

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer UCB Biopharma nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Delen